These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
461 related articles for article (PubMed ID: 34769131)
1. Histone Modification in NSCLC: Molecular Mechanisms and Therapeutic Targets. Bajbouj K; Al-Ali A; Ramakrishnan RK; Saber-Ayad M; Hamid Q Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769131 [TBL] [Abstract][Full Text] [Related]
2. Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells. Mateen S; Raina K; Jain AK; Agarwal C; Chan D; Agarwal R Epigenetics; 2012 Oct; 7(10):1161-72. PubMed ID: 22965008 [TBL] [Abstract][Full Text] [Related]
3. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells. Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120 [TBL] [Abstract][Full Text] [Related]
4. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer. Zhong S; Fields CR; Su N; Pan YX; Robertson KD Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644 [TBL] [Abstract][Full Text] [Related]
5. Epigenetic priming of non-small cell lung cancer cell lines to the antiproliferative and differentiating effects of all-trans retinoic acid. Greve G; Schiffmann I; Lübbert M J Cancer Res Clin Oncol; 2015 Dec; 141(12):2171-80. PubMed ID: 26008188 [TBL] [Abstract][Full Text] [Related]
6. Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope? Mamdani H; Jalal SI Front Cell Dev Biol; 2020; 8():582370. PubMed ID: 33163495 [TBL] [Abstract][Full Text] [Related]
7. DNA and histone modifications as potent diagnostic and therapeutic targets to advance non-small cell lung cancer management from the perspective of 3P medicine. Zhang G; Wang Z; Song P; Zhan X EPMA J; 2022 Dec; 13(4):649-669. PubMed ID: 36505890 [TBL] [Abstract][Full Text] [Related]
8. Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives. Schiffmann I; Greve G; Jung M; Lübbert M Epigenetics; 2016 Dec; 11(12):858-870. PubMed ID: 27846368 [TBL] [Abstract][Full Text] [Related]
9. Histone modifications in head and neck squamous cell carcinoma. Mao W; Wang B; Huang R; Sun Z; Yan M; Dong P Front Oncol; 2024; 14():1427725. PubMed ID: 38983924 [TBL] [Abstract][Full Text] [Related]
10. KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling. Wagner KW; Alam H; Dhar SS; Giri U; Li N; Wei Y; Giri D; Cascone T; Kim JH; Ye Y; Multani AS; Chan CH; Erez B; Saigal B; Chung J; Lin HK; Wu X; Hung MC; Heymach JV; Lee MG J Clin Invest; 2013 Dec; 123(12):5231-46. PubMed ID: 24200691 [TBL] [Abstract][Full Text] [Related]
11. Targeting epigenetic DNA and histone modifications to treat kidney disease. Fontecha-Barriuso M; Martin-Sanchez D; Ruiz-Andres O; Poveda J; Sanchez-Niño MD; Valiño-Rivas L; Ruiz-Ortega M; Ortiz A; Sanz AB Nephrol Dial Transplant; 2018 Nov; 33(11):1875-1886. PubMed ID: 29534238 [TBL] [Abstract][Full Text] [Related]
12. Histone Modifications as Molecular Targets in Nasopharyngeal Cancer. Shyamasundar S; Dheen ST; Bay BH Curr Med Chem; 2016; 23(2):186-97. PubMed ID: 26549431 [TBL] [Abstract][Full Text] [Related]
14. Downregulation of the long noncoding RNA GAS5-AS1 contributes to tumor metastasis in non-small cell lung cancer. Wu Y; Lyu H; Liu H; Shi X; Song Y; Liu B Sci Rep; 2016 Aug; 6():31093. PubMed ID: 27489122 [TBL] [Abstract][Full Text] [Related]
15. Novel histone deacetylase inhibitors derived from Magnolia officinalis significantly enhance TRAIL-induced apoptosis in non-small cell lung cancer. Liu Y; Tong Y; Yang X; Li F; Zheng L; Liu W; Wu J; Ou R; Zhang G; Hu M; Liu Z; Lu L Pharmacol Res; 2016 Sep; 111():113-125. PubMed ID: 27268146 [TBL] [Abstract][Full Text] [Related]
16. Transcriptional repression of histone deacetylase 3 by the histone demethylase KDM2A is coupled to tumorigenicity of lung cancer cells. Dhar SS; Alam H; Li N; Wagner KW; Chung J; Ahn YW; Lee MG J Biol Chem; 2014 Mar; 289(11):7483-96. PubMed ID: 24482232 [TBL] [Abstract][Full Text] [Related]
17. Histones and lung cancer: Are the histone deacetylases a promising therapeutic target? Petta V; Gkiozos I; Strimpakos A; Syrigos K Cancer Chemother Pharmacol; 2013 Nov; 72(5):935-52. PubMed ID: 24036844 [TBL] [Abstract][Full Text] [Related]
18. Regulation of EP receptors in non-small cell lung cancer by epigenetic modifications. Gray SG; Al-Sarraf N; Baird AM; Cathcart MC; McGovern E; O'Byrne KJ Eur J Cancer; 2009 Nov; 45(17):3087-97. PubMed ID: 19818596 [TBL] [Abstract][Full Text] [Related]
19. A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer. Tang YA; Wen WL; Chang JW; Wei TT; Tan YH; Salunke S; Chen CT; Chen CS; Wang YC PLoS One; 2010 Sep; 5(9):e12417. PubMed ID: 20856855 [TBL] [Abstract][Full Text] [Related]
20. Rebelled epigenome: histone H3S10 phosphorylation and H3S10 kinases in cancer biology and therapy. Komar D; Juszczynski P Clin Epigenetics; 2020 Oct; 12(1):147. PubMed ID: 33054831 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]